NewLink Genetics Corporation (NASDAQ: NLNK) announced today results of its Phase 3 clinical trial for algenpantucel-L for patients with resected ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trader Talk Trading Halts

SunTrust Downgrades NewLink Genetics (NLNK) to NeutralMay 11, 2016 6:49 AM Mizuho Securities Cuts Price Target on NewLink Genetics (NLNK) Following Failed IMPRESS Trial May 10, 2016 1:22 PM Baird Highlighgs NewLink Genetics' (NLNK) IDO Program Amid Algenpantucel-L FailureMay 10, 2016 6:29 AM NewLink Genetics Announces Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic CancerMay 9, 2016 4:01 PM